이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Theriva Biologics 과거 수익 실적

과거 기준 확인 0/6

Theriva Biologics의 수입은 연평균 -0.3%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 증가했습니다(19.1%).

주요 정보

-0.3%

수익 성장률

60.6%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	n/a
자기자본 수익률	-80.5%
순이익	n/a
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

David Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)

Mar 07

Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?

Feb 04

수익 및 비용 분석

Theriva Biologics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NYSEAM:TOVX 수익, 비용 및 수입 (USD Millions )
날짜	수익	G+A 비용	R&D 비용
30 Jun 24	-22	7	15
31 Mar 24	-19	8	15
31 Dec 23	-18	8	14
30 Sep 23	-19	8	13
30 Jun 23	-21	9	12
31 Mar 23	-20	8	12
31 Dec 22	-20	8	12
30 Sep 22	-19	8	11
30 Jun 22	-17	7	11
31 Mar 22	-16	7	9
31 Dec 21	-23	6	8
30 Sep 21	-21	5	6
30 Jun 21	-20	5	5
31 Mar 21	-21	5	5
31 Dec 20	-13	5	5
30 Sep 20	-13	5	6
30 Jun 20	-15	5	9
31 Mar 20	-16	5	10
31 Dec 19	-16	5	11
30 Sep 19	-28	4	11
30 Jun 19	-26	5	10
31 Mar 19	-27	5	11
31 Dec 18	-25	6	12
30 Sep 18	-8	7	13
30 Jun 18	-22	7	15
31 Mar 18	-22	7	16
31 Dec 17	-22	8	19
30 Sep 17	-27	9	22
30 Jun 17	-18	9	25
31 Mar 17	-19	10	27
31 Dec 16	-27	10	29
30 Sep 16	-36	9	31
30 Jun 16	-34	9	34
31 Mar 16	-42	9	35
31 Dec 15	-44	8	33
30 Sep 15	-39	7	29
30 Jun 15	-37	7	23
31 Mar 15	-28	7	18
31 Dec 14	-20	6	14
30 Sep 14	-18	5	12
30 Jun 14	-16	6	10
31 Mar 14	-14	5	8

양질의 수익: TOVX 은(는) 현재 수익성이 없습니다.

이익 마진 증가: TOVX 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: TOVX 은(는) 수익성이 없으며 지난 5년 동안 연간 0.3% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 TOVX 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: TOVX 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: TOVX 현재 수익성이 없기 때문에 마이너스 자본 수익률( -55.79% )을 갖습니다.

Theriva Biologics 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Synthetic Biologics, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

Synthetic Biologics, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Synthetic Biologics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Recent updates

Theriva Biologics, Inc. Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

New major risk - Shareholder dilution

Theriva Biologics, Inc., Annual General Meeting, Oct 31, 2024

High number of new and inexperienced directors

Theriva Biologics, Inc. has filed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

New major risk - Financial position

Theriva Biologics, Inc. Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

New major risk - Share price stability

Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation

Theriva Biologics, Inc. has filed a Follow-on Equity Offering in the amount of $1.235303 million.

Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

New minor risk - Share price stability

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Theriva Biologics, Inc., Annual General Meeting, Oct 02, 2023

New minor risk - Shareholder dilution

New major risk - Market cap size

New minor risk - Share price stability

Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery

Theriva Biologics, Inc. Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

High number of new and inexperienced directors

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004

Theriva Biologics, Inc. Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics, Inc., Annual General Meeting, Sep 30, 2022

Synthetic Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.

Synthetic Biologics, Inc. Notifies Clearance of Safety Evaluation Period

High number of new and inexperienced directors

Synthetic Biologics, Inc. Reports Positive Safety Data on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Price target increased to US$1.63

Synthetic Biologics, Inc. Announces Peer-Reviewed Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients with Advanced Solid Tumors

Synthetic Biologics, Inc. (NYSEAM:SYN) signed a definitive agreement to acquire VCN Biosciences SL from Grifols Innovation and New Technologies Limited and others for $85.6 million.

Synthetic Biologics Provides Update on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

David Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)

Synthetic Biologics, Inc. Announces Clinical Development and Operational Update

Insider recently bought US$174k worth of stock

Synthetic Biologics, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

New 90-day high: US$1.17

Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?

New 90-day high: US$0.50

Synthetic Biologics, Inc. Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

Synthetic Biologics, Inc. Announces Executive Changes

Synthetic Biologics, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$0.31

New 90-day low: US$0.31

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2B Clinical Study of SYN-010 in IBS-C Patients

New 90-day low: US$0.45

Synthetic Biologics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

New 90-day high - US$0.71

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기